1 BTC
=
- USD
Nuvation Bio Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Market Statistics
Trading Metrics
How to Buy NUVB
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy NUVB
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesKerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 Class A shares for approximately $904,000 on April 6, 2026, reducing his direct holdings by 79%. However, he retains 53,000 shares and 700,000 stock options, suggesting the sale is a routine profit-taking exercise rather than a loss of confidence in the company. Nuvation Bio, a clinical-stage oncology biotech with promising pipeline candidates, reported a net loss of $204.6 million but this is typical for R&D-heavy biotech firms.
The Schall Law Firm is investigating Nuvation Bio Inc. for potential securities law violations following the company's Q4 2025 earnings report. The company revealed that 75% of treatment discontinuations for its IBTROZI oncology therapy occurred in later-line patient populations, contributing to a gap between patient starts and revenue growth. The stock fell 25.3% following this disclosure, prompting the investigation into whether the company issued false or misleading statements.
Pomerantz Law Firm has filed class action lawsuits against PayPal Holdings and Snowflake Inc., with deadlines for investors to join. PayPal announced disappointing Q4 2025 earnings, CEO departure, and withdrawn 2027 guidance due to macroeconomic factors and operational issues. The firm is also investigating claims on behalf of Nuvation Bio investors.
Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.
